• Arena will launch lorcaserin with or without partner
• Pfizer stops another figitumumab trial
• Aveo proves investors still lack appetite for biotech IPOs
• Genetix raises $35M to advance gene therapies
• Merck joins consortium on vax plant
• Aveo Pharma delays IPO, at least briefly
• Bay Area biotech blueprints $100M China biologics hub
• BioSante shares surge as cancer vax performs in small study
…full story

• Science Daily Biotech: How Electricity Moves Through Cells: Finding Has Implications for Improving Energy Efficiency Researchers have created a molecular image of a system that moves electrons between proteins in cells. The achievement is a ... > full story …full story

•  Duquesne University, Agilent Technologies Establish Mass Spectrometry Centre of Excellence to Study Diseases
•  Wageningen UR develops cost-saving technology for seed research
• Immune cells use bungee of death to kill dangerous cells, shows new research
• Svein Lien appointed new CEO of Biotec Pharmacon ASA
• Vilcek prizes in biomedical science awarded
• University of Michigan scientists discover bone marrow can harbor HIV-infected cells
• Australia’s Top 20 cancer drugs to reach sales of $1 billion by 2018
• Bavarian Nordic Successfully Completes End of Phase II Meeting for PROSTVAC
…full story

• OnBioVC | Welcome…New Feature Friday…Maybe?
• OrbiMed | Looking for Some (More) of This?
• OnBioVC | Thanks to Our Sponsors
• Nautilus Neurosciences, Inc.: Series A $14.5M
• NABsys, Inc.: Series B $7M
• Eleven Biotherapeutics, Inc.: Series A $35M
• Pulmonx, Inc.: Series C $32M
• Seahorse Bioscience, Inc.: Series D $5M
…full story

• Rare Monkey Succumbs to Cryptococcosis
• Fungal Degradation of Polyurethane
• Mycology at the New “Popular Science” Archive
• Lockwood Heading for Brasil
• Deaths from Mushrooms in Zimbabwe
…full story

• Access Pharmaceuticals Reports Significant Oral Bioavailability of Cobalamin(TM) Oral Insulin in Additional Studies
• Seattle Genetics Expands Antibody-Drug Conjugate Patent Portfolio
• Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications
• Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced Melanoma
• Cardium Reports on Registered Direct Offering
• Exelixis Announces Restructuring
• Cardium's Exchange Listing Compliance Plan Accepted by NYSE AMEX
• Genta Inc. Announces $25 Million Financing
…full story

• Medicare agency adds ex-Va. official, plans reorganization - The Hill's Blog Briefing Room
• Delegate Steve Landes Wins “Virginia Bioscience Legislative Leadership Award”
• US House GOP Whip Eric Cantor on Biotech
• Capital Gains Exclusion on Technology Investments Goes to VA Governor
• DNA Co. Intrexon Raises $17.4M
• Gauze is good for Newport News firm
• Anti- Embryonic Stem Cell Language in VA House Budget
• VA Senate Rejects Governor's Econ Dev Plan- Except Biotech!
…full story

• Featured - Mysterious cosmic 'dark flow' tracked deeper into universe
• Featured - Conquering the chaos in modern, multiprocessor computers
• Featured - Game on? Video-game ownership may interfere with young boys' academic functioning
• Featured - Prehistoric response to global warming informs human planning today
• Featured - Students' perceptions of Earth's age influence acceptance of human evolution
• Featured - Genome of entire family reveals parents give kids fewer gene mutations than thought
• Featured - Researchers demonstrate link between brain chemical, decline in schizophrenia
• Featured - Confidence is key to gauging impressions we make
…full story

• European Biotechnica Award 2010: Competition entries now being accepted
• InVitria Optimizes Hybridoma Cell Culture with New Product Zap-Hybridoma
• EnzymeRx Provides a Clinical Update on Pegsitacase
• Vetter Wins the Axia Award
• clinicalprojects international GmbH Announces Further Growth into New Therapeutic and ...
• InVitria Sponsors 2010 Biomanufacturing Summit
• Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of ...
• GATC Biotech Orders Europe’s First HiSeq 2000 for Commercial Use
…full story

• Biotechnology Techniques for Tracing Food Pathogens
• E. coli O157:H7 Duped by Built-in Food Safety Mechanism
• Summit on Food Safety
• Digital Education in the Sciences
• What Fascinates You?
• Epigenetic Markers Change with Age
• Cervical Cancer Immunoassay Improves Diagnostic Accuracy
• Evolution of Bioprocessing
…full story

• Fitzsimons: From vacant Army post to medical promised land
• March 2 is the 2010 BioBeers Launch at Twisted Pine in Boulder
• Bioscience Day at the Capitol: Patrick Kelly, Biotechnology Industry Association, YouTube Now Posted
• CEO Collar leaves Colorado BioScience Association
• Colorado BioScience Association's CEO moves on
• Archived from Jan 22, 2010 -- BioScience Day at Capitol to showcase industry Jan. 27
• Recap: Bioscience Day at the Capitol
• January 22, 2010 - InDevR Featured in the Boulder County Business Report
…full story

• America's got talent–can it keep it?
• H1N1dsight is a wonderful thing
• Ark's gene therapy stumbles at the finish line
• Monsanto's alfalfa reaches Supreme Court
• GSK/Sirtris compounds dogged by assay artifacts
• US biodefense contracts continue to lure biotechs
• Ride 'n Drive on government waste …full story

• How to improve R&D productivity: the pharmaceutical industry's grand challenge
• Membrane transporters in drug development
• Protein aggregation diseases: pathogenicity and therapeutic perspectives
• Challenges with advanced therapy medicinal products and how to meet them
• Type 1 diabetes
• Vaccines: New vaccine platform?
• Anticancer drugs: Actively targeting mTOR …full story

• Allos Therapeutics: 08/10/09 Allos Therapeutics Announces FDA Advisory Committee to Review Pralatrexate for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma …full story

• Affygility: April 23, 2009
• Affygility Solutions releases Potent Compound Safety Self-Assessment Tool
• Affygility Solutions is pleased to announce the release of its Potent Compound Safety Self-Assessment Tool - PCSSAT™ to ensure safe potent compound handling.
• Based on industry expertise, PCSSAT™ allows life science companies the ability to self-evaluate their programs, procedures, and operational practices …full story